Very low doses of rituximab in autoimmune hemolytic anemia-an open-label, phase II pilot trial.

Journal: Frontiers in medicine
Published Date: Dec 20, 2024

Abstract

INTRODUCTION: Although rituximab is approved for several autoimmune diseases, no formal dose finding studies have been conducted. The amount of CD20+ cells differs significantly between autoimmune diseases and B-cell malignancies. Hence, dose requirements of anti-CD20 therapies may differ accordingly.

Authors

  • Miriam M Moser
    Department of Medicine I, Division for Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria.
  • Renate Thalhammer
    Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
  • Christian Sillaber
    Department of Medicine I, Division of Hematology, Medical University of Vienna, Vienna, Austria.
  • Ulla Derhaschnig
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
  • Christa Firbas
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
  • Ulrich Jäger
    Department of Medicine I, Division of Hematology, Medical University of Vienna, Vienna, Austria.
  • Bernd Jilma
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
  • Christian Schoergenhofer
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals